Search PubMed⌕ Search

Biomedical subjects

N Sawamura

Publications and source records attributed to N Sawamura.

27 records · Page 2Linked to original sources
PubMed1985

[Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].

The effect of high-dose metoclopramide (2 mg/kg, 4 times every 2 hours) on the emesis of patients treated with CDDP (80 mg/m2) was examined by randomized control trial. The above metoclopramide regimen significantly suppressed the frequency of vomiting on the day of CDDP administration. The duration of nausea and anorexia after CDDP treatment was also shortened by high-dose metoclopramide administration.

Adult↗
PubMed1985

[The control of chemotherapy-induced nausea and vomiting].

A growing interest has been shown in antiemetics with important advances in understanding the physiology of vomiting and the development of new anticancer agents having high emetic potential such as cisplatin. At present, high-dose metoclopramide, dexamethasone and butyrophenones have shown effective antiemetic action. In addition, antiemetic drug combinations that affect more than one neurotransmitter receptor have achieved improved emesis control. While improvements have been made in acute chemotherapy-induced emesis, anticipatory and delayed emesis is still a difficult problem. Further studies under well-designed trials are necessary to establish which of the available agents, doses, routes of administration, and schedules are best for reducing emesis depending on the chemotherapeutic drugs used.

Antiemetics↗
PubMed1984

[Significance of the bioclean room during the treatment of lung cancer].

The effectiveness of a vertical air flow room using HEPA filter (class 5000) was studied in relation to the prevention of infection during induction chemotherapy for primary lung cancer and metastatic pulmonary tumors. From November 1982 to July 1983, 12 patients (11 primary lung cancer: 9 small cell carcinoma, 2 non-small cell carcinoma and 1 metastatic pulmonary tumor) were treated in the bioclean room, while 14 patients (1 small cell carcinoma, 13 non-small cell carcinoma) were treated in conventional room during this period as control. Partial response was observed in 6 patients with small cell carcinoma treated in the bioclean room and 4 patients with non-small cell carcinoma treated in the conventional room. In patients treated in the bioclean room, the median day of stay in the room was 21 ranged 9 to 43. The leukocyte counts in the peripheral blood less than 1500/mm3 and 1000/mm3 were observed in 6 and 4 cases, respectively. Decrease in granulocyte counts less than 500/mm3 was observed in 6 cases. Only one patient with leukocyte count of 800 (granulocyte count 104) experienced fever higher than 38 C lasting 8 days. On the other hand, in 14 patients treated in the conventional room, leukocytopenia less than 1500/mm3 and 1000/mm3 was observed in 7 and 0 cases, respectively. Granulocytopenia less than 500/mm3 was observed in 8 cases, and 7 patients experienced fever higher than 38 C. Number of non-viable particles in the bioclean room ranged from 2.9 to 6.8 X 10(2)/ft3. Organisms isolated from the bioclean room and from the skin of patients were normal flora, and the numbers of colonies detected from the skin of patients decreased 1-2 weeks after the beginning of treatment in the bioclean room. The usefulness of a vertical air flow room during chemotherapy of lung cancer, especially of small cell carcinoma, was suggested.

Adult↗